IDEAYA Biosciences (IDYA)

IDEAYA Biosciences is a precision oncology company built around the concept of synthetic lethality and a lead near-commercial asset, darovasertib, in uveal melanoma. After several years as a “story stock”, the company is now at a point where pivotal data, registrational trial starts and a deep pipeline of MAT2A/PRMT5/PARG and ADC combinations all converge into a crowded 2026–2027 catalyst map.

The headline from the J.P. Morgan 2026 update is simple (see IDEAYA’s January 11, 2026 business update and 2026 objectives press release): approximately 1.1 billion dollars of cash, cash equivalents and marketable securities as of 30 September 2025, a guided runway into 2030, and the intention to run four registrational trials in parallel in 2026 across darovasertib and IDE849, while advancing multiple first-in-class synthetic lethality programs into Phase 1. This is an unusually strong balance sheet for a roughly 3.3 billion market-cap development- stage biotech.

At the same time, the equity story is far from de-risked. Darovasertib needs to confirm its Phase 2 signal in a randomized setting (OptimUM-02) and then translate into real-world adoption across several uveal melanoma settings. The broader pipeline is scientifically attractive but inherently complex, with many moving parts and heavy reliance on external partners for certain combinations and ADCs. The stock currently trades in the high-30s, not far from its 52-week high, with a strong “Buy” consensus and an average analyst target close to 50 dollars.

This report is descriptive and educational. It is not a Buy/Sell recommendation and should be read as a structured dossier to support your own due diligence, not as a shortcut to a decision.

Figures are approximate and based on public sources around early January 2026. Key balance-sheet figures are drawn from IDEAYA’s Q3 2025 financial results press release, the company’s Form 10-Q for the quarter ended September 30 2025 e la corporate presentation di dicembre 2025. Always check updated data before using any numbers in a trading or investment context.

Darovasertib (IDE196) – PKC inhibitor in uveal melanoma

• Indications: metastatic uveal melanoma (MUM) in combination with crizotinib (first-line), neoadjuvant primary uveal melanoma, adjuvant UM.
• Pivotal programme: OptimUM-02, an integrated Phase 2/3 trial in first-line MUM HLA-A2-negative – see clinicaltrials.gov NCT05987332 and IDEAYA’s Dec 11 2025 full-enrollment press release. The Phase 2 portion is intended to support potential accelerated approval based on PFS, with the Phase 3 portion powering overall survival.
• Evidence so far: prior single-arm Phase 2 data (OptimUM-01) showed median PFS around 7 months and encouraging median OS compared with historical expectations in front-line MUM, with a high disease control rate and a tolerable safety profile, as summarized in the Q3 2025 business update.
• Market context: no approved systemic therapy for HLA-A2-negative MUM, significant unmet need along the uveal melanoma patient journey, and potential for use in both primary and metastatic settings.

IDE397 – MAT2A inhibitor in MTAP-deleted tumours

• Biology: exploits MTAP deletion in solid tumours by targeting the methionine cycle through MAT2A inhibition, creating a synthetic lethality relationship.
• Status: Phase 2 monotherapy expansion in urothelial and lung cancer with MTAP deletion; multiple combination programmes planned or ongoing, including Trodelvy (Gilead’s Trop-2 ADC) and IDE892 (PRMT5).
• Key 2026 target: clinical data update for IDE397 + Trodelvy at a medical conference, and enabling a wholly-owned IDE397 + IDE892 combination.

ADC and DNA damage response combinations

• IDE849 / SHR-4849 (DLL3 TOP1i ADC): DLL3-targeted antibody-drug conjugate for small-cell lung cancer and other DLL3-expressing neuroendocrine tumours. The company is targeting patient dosing in NETs and additional DLL3 tumours, with plans to combine IDE849 with IDE161 (PARG inhibitor).
• IDE161 (PARG inhibitor): Phase 1 monotherapy dose optimisation in HRD-positive solid tumours, with the goal of enabling combinations with ADCs such as IDE849. PARG inhibition hits a complementary node in the DNA damage repair pathway relative to PARP.

Next-generation synthetic lethality pipeline

• IDE892 (PRMT5MTA): PRMT5 inhibitor designed to work in MTAP-deleted cancers. IND is cleared; the company aims to enable a wholly-owned combination with IDE397 in 2026.
• IDE034: B7H3/PTK7 bispecific ADC (TOP1i payload) with IND cleared in late 2025 and early development in multiple solid tumours, under a collaboration with Biocytogen.
• IDE574: dual KAT6/7 inhibitor targeting 8p11-amplified solid tumours; IND was planned for late 2025 and the company now guides for Phase 1 start in the first quarter of 2026.
• Pol Theta (IDE705) and Werner (IDE275): earlier-stage programmes in collaboration with GSK, focusing on HR-deficient tumours and MSI-high cancers.

The breadth of the pipeline is a positive differentiator but also a source of execution risk: a single company is attempting to advance multiple first-in-class agents in parallel, often in complex combinations.

Cash position and capital structure

As of 30 September 2025, IDEAYA reported approximately 1.14 billion dollars in cash, cash equivalents and marketable securities, as detailed in its Q3 2025 financial results press release and related Form 10-Q. Management has stated – and reiterated in the January 11 2026 J.P. Morgan update – that this level of capital is expected to fund operations into 2030, assuming current plans.

The cash position was significantly strengthened in 2025 by a 210 million dollar upfront payment from Servier related to the darovasertib licensing deal, as well as milestone and collaboration funding from partners such as Gilead and GSK. The company remains loss-making on a GAAP basis and will likely continue to burn capital as multiple registrational and early-stage trials progress. However, the starting point is far stronger than that of many peers, reducing near-term pressure for dilutive equity raises if the clinical data flow remains reasonably favourable.

Merlintrader Health Score – balance-sheet component

On the specific “Balance sheet/Runway” pillar of the Merlintrader Health Score (30% weight), IDEAYA would rank in the upper tier of development-stage biotech: large cash buffer, diversified collaboration funding and no apparent debt overhang. The main caveat is that capital will still be consumed at a high rate, given the ambition of running multiple global registrational programmes in parallel.

Revenue sources and collaborations

• Core model: no product revenues yet; reported revenues consist mainly of collaboration and license income from partners.
• Servier (darovasertib): exclusive licence outside the United States with IDEAYA retaining US commercial rights. The company is eligible for substantial regulatory and commercial milestones and double-digit royalties on ex-US sales.
• Gilead (IDE397 + Trodelvy): clinical study collaboration; IDEAYA sponsors the trial, Gilead provides Trodelvy at no cost and retains all commercial rights to Trodelvy.
• GSK (Pol-Theta, Werner): discovery-stage synthetic lethality programmes with option/license economics.
• Hengrui (IDE849): exclusive licence outside Greater China for the DLL3 ADC; Hengrui retains territorial rights in China.
• Biocytogen (IDE034): partnership for the B7H3/PTK7 bispecific ADC.

Collaborations help de-risk development costs and validate the biology but also dilute the ultimate economics on some programs. For darovasertib, the US market remains fully owned by IDEAYA, which is important if the drug becomes a standard of care in uveal melanoma.

Near-term and 2026 milestones

• Q1 2026: topline progression-free survival results from the Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in first-line metastatic uveal melanoma (HLA-A2 negative). This readout is central to the accelerated approval thesis and timing is explicitly guided in the Dec 11 2025 OptimUM-02 update and the Jan 11 2026 J.P. Morgan business update.
• 2026 (H1): updates on darovasertib Phase 3 trials in neoadjuvant and adjuvant UM, with at least three registrational studies planned or underway across the UM/MUM patient journey.
• H1 2026: IDE397 + Trodelvy combination data at a medical conference in MTAP-deleted urothelial and lung cancers, testing the broader MTAP pathway strategy beyond uveal melanoma.
• 2026: IDE397 + IDE892 (PRMT5) wholly-owned combination entering the clinic, plus continued monotherapy expansion.
• Q1 2026: IDE574 (dual KAT6/7 inhibitor) Phase 1 initiation following IND clearance in early 2026, adding another novel target into the clinical portfolio.
• Throughout 2026: expansion of IDE849 (DLL3 ADC) dosing in DLL3 tumours and enabling combinations with IDE161, as well as early clinical activity readouts across the ADC/DDR combination space.

Beyond 2026 – medium-term validation points

• Overall survival data from darovasertib programmes, both in metastatic and earlier-line uveal melanoma, which will be critical to moving from accelerated approvals to full approvals and to convincing payers and clinicians.
• Durability and breadth of response for IDE397-based combinations in MTAP-deleted tumours, and whether the biomarker strategy can support meaningful commercial positioning in relatively crowded tumour types such as NSCLC.
• Early proof-of-concept signals from PARG inhibition and ADC/DDR combinations (IDE161 + IDE849, IDE034, etc.), which would support the idea that IDEAYA is not a one-drug company but a genuine platform with multiple shots on goal.
• Strategic choices around the next wave of programmes (Pol-Theta, Werner, KAT6/7, platform programmes): management has hinted that options will be evaluated in 2026, potentially leading to further partnering, focus or pruning decisions.

For trading-oriented readers, the Q1 2026 PFS readout and J.P. Morgan/major conference updates are likely to be the main catalysts, but the deeper equity story depends on whether darovasertib can build a durable, multi-setting franchise and whether at least one of the MTAP/ADC/DDR programmes becomes a second pillar.

Institutional profile and trading liquidity

IDYA now trades firmly in the mid-cap biotech bracket, with daily dollar volume that is generally adequate for both institutional investors and active traders. The stock has attracted a broad set of specialist healthcare funds as well as generalist growth investors, thanks to the combination of a strong balance sheet and high-profile late-stage assets.

The float is largely institutional, which can support price stability in normal times but also amplify moves when sentiment shifts quickly across the specialist biotech community. Option open interest has been rising, particularly around key event windows, reflecting growing interest in directional bets rather than purely buy-and-hold positions.

Short interest and hedge fund angle

Recent data indicate a short interest in the high single digits as a percentage of float, with a days-to-cover ratio in the mid-single digits based on average trading volume. This is not extreme, but high enough to matter around binary events: strong positive data could force covering and amplify upside moves, while negative surprises could see shorts pressing their advantage.

In practical terms, IDYA behaves less like a thin, illiquid small-cap and more like a liquid event-driven mid-cap: the tape can move fast around news, but most investors can still enter or exit without massive slippage under normal conditions.

Upside scenario (multi-pillar platform)

• OptimUM-02 shows clearly positive PFS with an acceptable safety profile, leading to a constructive FDA dialogue and a viable path to accelerated approval in first-line MUM.
• Neoadjuvant and adjuvant darovasertib trials confirm clinical benefit, supporting a franchise across the UM patient journey with significant duration of therapy.
• IDE397 and at least one ADC/DDR combination generate compelling mid-stage data in MTAP-deleted and DLL3-positive tumours, positioning IDEAYA as a multi-asset precision-oncology company rather than a single-drug story.
• The strong balance sheet allows the company to reach key inflection points without punitive dilution, and partnership economics provide additional non-dilutive funding.

Base case (darovasertib-driven, platform optionality)

• Darovasertib delivers “good but not perfect” data: enough for some form of approval and meaningful uptake in specialist centres, but with label, safety or competition considerations that cap peak revenue expectations.
• IDE397 and the MTAP-pathway programmes produce promising but mixed signals, leading to selective advancement and additional partnering rather than a fully internalised commercial strategy.
• The stock trades largely on darovasertib news flow, with the rest of the pipeline acting as background optionality that may or may not be recognised in the valuation.

Downside case (clinical or safety setbacks)

• OptimUM-02 fails to demonstrate a meaningful PFS benefit or reveals tolerability issues that limit regulatory enthusiasm or real-world use.
• Key synthetic lethality programmes encounter safety or efficacy hurdles that delay development or force strategic resets in MTAP-deleted or HRD-positive tumours.
• The company still has substantial cash, but the equity market begins to view it as a “preclinical platform with expensive lessons learned”, compressing valuation multiples and making future capital raises more painful.

IDEAYA Biosciences è una biotech di oncologia di precisione costruita attorno al concetto di synthetic lethality e ad un asset principale, darovasertib, in uveal melanoma. Dopo anni da “titolo da storia”, l’azienda è arrivata al punto in cui dati pivotal, avvio di trial registrativi e una pipeline ampia su MAT2A/PRMT5/PARG e ADC si concentrano tutti in una mappa di catalyst molto affollata tra il 2026 e il 2027.

Il messaggio chiave dall’aggiornamento al J.P. Morgan 2026 è chiaro: circa 1,1 miliardi di dollari di cassa, equivalenti e titoli a breve termine al 30 settembre 2025, runway dichiarata fino al 2030 e obiettivo di gestire almeno quattro trial registrativi nel 2026 su darovasertib e IDE849, mentre una serie di programmi di synthetic lethality di nuova generazione entra in Fase 1. Per una biotech da poco più di 3 miliardi di market cap, è una struttura finanziaria insolitamente robusta.

Dall’altra parte, la storia azionaria è tutt’altro che de-risked. Darovasertib deve confermare il segnale di Fase 2 in un trial randomizzato (OptimUM-02) e poi tradursi in adozione reale lungo tutto il percorso del paziente con uveal melanoma. Il resto della pipeline è molto interessante, ma complesso: molti programmi, combinazioni multiple, forte dipendenza dal lavoro con partner esterni. Il titolo oggi scambia nella fascia alta dei 30 $, non lontano dai massimi a 52 settimane, con consenso “Strong Buy” e target medi intorno ai 50 $.

Questo report è descrittivo e didattico. Non è una raccomandazione di acquisto o vendita e va letto come un dossier strutturato per supportare la tua due diligence, non come scorciatoia per una decisione.

Tutti i numeri sono indicativi e basati su fonti pubbliche attorno a inizio gennaio 2026. I dati di cassa e runway derivano dal comunicato Q3 2025, dal relativo Form 10-Q e dalla presentazione corporate di dicembre 2025. Prima di usarli in qualunque decisione operativa è indispensabile verificare i dati aggiornati sulle fonti ufficiali o tramite il tuo intermediario.

Darovasertib (IDE196) – PKC inhibitor in uveal melanoma

• Indicazioni: melanoma uveale metastatico (MUM) in prima linea in combinazione con crizotinib (HLA-A2 negativo), neoadiuvante e adiuvante in uveal melanoma primario.
• Programma registrativo: OptimUM-02, trial integrato Fase 2/3. La parte di Fase 2 su PFS è pensata per supportare una potenziale approvazione accelerata negli Stati Uniti; la Fase 3 punta su OS e conferma definitiva del beneficio. Il disegno è descritto nel record NCT05987332 e nel comunicato di dicembre 2025.
• Dati ad oggi: nello studio singolo-braccio OptimUM-01, la combo darovasertib + crizotinib ha mostrato un PFS mediano intorno ai 7 mesi e una OS mediana favorevole rispetto ai benchmark storici, come riportato nel business update del 4 novembre 2025.

IDE397 – MAT2A in tumori MTAP-deleted

• Logica: colpire il ciclo della metionina in tumori con delezione MTAP tramite inibizione di MAT2A, sfruttando una relazione di synthetic lethality.
• Stato: espansioni di Fase 2 in monoterapia in tumori uroteriali e polmone con MTAP deletion; programmi di combinazione in preparazione o avviati (con Trodelvy e con IDE892).

ADC e combinazioni DNA damage response

• IDE849 / SHR-4849: ADC su DLL3 con payload TOP1i, mirato a SCLC e altri tumori neuroendocrini DLL3-positivi; previste espansioni e combinazioni con IDE161.
• IDE161: inibitore PARG in Fase 1, con l’obiettivo di abilitare combinazioni con ADC e sfruttare vulnerabilità nei tumori HRD-positivi.
• IDE892, IDE034, IDE574: rispettivamente PRMT5, ADC bispecifico B7H3/PTK7 e inibitore KAT6/7; tutti parte della “seconda ondata” della pipeline di synthetic lethality descritta nella presentazione corporate di dicembre 2025.

Il vantaggio è la diversificazione scientifica; lo svantaggio è che una pipeline così densa richiede enormi capacità organizzative e di capitale per arrivare in fondo ai programmi più promettenti senza disperdersi.

Cassa, struttura del capitale, dilution

Al 30 settembre 2025 IDEAYA riportava circa 1,14 miliardi di dollari tra cassa, equivalenti e titoli negoziabili, come indicato nel comunicato dei risultati del terzo trimestre 2025 e nel relativo Form 10-Q. La stessa cifra viene ripresa e sintetizzata nell’aggiornamento J.P. Morgan 2026, dove management ribadisce una runway fino al 2030.

La cassa è stata rafforzata in particolare dall’upfront da 210 milioni di dollari ricevuto da Servier sulla licenza di darovasertib, oltre a milestone e finanziamenti da Gilead, GSK e altri partner. L’azienda è ancora in perdita e lo resterà probabilmente per diversi anni, ma parte da una posizione di forza rispetto alla media delle biotech pre-ricavi: se i dati clinici tengono, la pressione per aumenti di capitale nel breve appare limitata.

Collaborazioni e ricavi

I ricavi di IDEAYA sono oggi quasi esclusivamente composti da upfront, milestone e rimborsi di costi da parte dei partner. Tra gli accordi principali:

• Servier per darovasertib fuori dagli Stati Uniti.
• Gilead per la combinazione IDE397 + Trodelvy.
• GSK per i programmi Pol-Theta e Werner.
• Hengrui per IDE849 al di fuori della Greater China.
• Biocytogen per l’ADC bispecifico IDE034.

Questi accordi alleggeriscono il fabbisogno di capitale e validano il razionale scientifico, ma riducono in parte le economics future. Il fatto che darovasertib resti interamente di IDEAYA negli Stati Uniti è però un elemento molto importante se il farmaco dovesse diventare standard di cura nei diversi setting di uveal melanoma.

Cosa aspettarsi nel 2026

• Q1 2026: PFS topline di OptimUM-02 (darovasertib + crizotinib in prima linea MUM HLA-A2-negativa) – evento chiave per l’ipotesi di approvazione accelerata, con timing esplicitamente indicato sia nel comunicato dell’11 dicembre 2025 sia nell’ update dell’11 gennaio 2026.
• 2026: avanzamento dei trial di Fase 3 di darovasertib in setting neoadiuvante e adiuvante UM, con l’obiettivo di costruire un intero “percorso” terapeutico.
• H1 2026: dati dalla combinazione IDE397 + Trodelvy in tumori MTAP-deleted, primo vero banco di prova a medio raggio per la strategia MAT2A.
• 2026: ingresso in clinica della combinazione IDE397 + IDE892, oltre ad aggiornamenti sulle monoterapie IDE161/IDE849.
• Q1 2026: avvio della Fase 1 del programma IDE574 (KAT6/7), come indicato nell’update J.P. Morgan 2026.

Oltre il 2026

• Dati su OS e durabilità del beneficio di darovasertib nelle varie indicazioni UM/MUM e percorso da approvazione accelerata a piena approvazione.
• Prove più robuste sull’impatto di IDE397/IDE892 e delle combinazioni ADC/DDR in tumori più comuni (NSCLC, SCLC, NET), dove la concorrenza è molto più affollata.
• Prime evidenze solide sui programmi più giovani (KAT6/7, Pol-Theta, Werner) e decisioni strategiche su cosa portare avanti, cosa licenziare e cosa eventualmente chiudere.

Dal punto di vista di chi fa trading di breve/medio periodo, il “cuore” del 2026 è rappresentato da OptimUM-02 e dai vari update al J.P. Morgan e alle conference principali. Ma per chi ragiona in ottica multi-anno, è decisivo capire se IDEAYA riuscirà a trasformarsi da “darovasertib-centrica” a vera piattaforma multi-pilastro.